Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03194971 | NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy | completed | — | 20 | Medical College of WisconsinOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04471844 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM(EF-32) | completed | N/A | 981 | NovoCure Ltd.INDUSTRY | 11 | Mar 30, 2026 |
| clinicaltrials |
| NCT07499141 | Use of Fluorescence in Gliomas(UFGAG) | completed | — | 41 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | completed | Phase 1 | 17 | Susan ChangOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02286167 | Glioma Modified Atkins-based Diet in Patients With Glioblastoma(GLAD) | completed | N/A | 25 | Wake Forest University Health SciencesOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03551249 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | completed | N/A | 20 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03475186 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | completed | Phase 2 | 75 | Wake Forest University Health SciencesOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT04044937 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms(UC-GlioFET) | completed | Phase 2 | 143 | Thomas HopeOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04391595 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | completed | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05431348 | Effect of stRess and exeRcize on the Outcome After Chemo-Radiation(ERROR) | completed | — | 42 | Maastricht Radiation OncologyOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | completed | Phase 1 | 37 | CureVacINDUSTRY | 3 | Feb 18, 2026 | clinicaltrials |
| NCT03450850 | Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma | completed | N/A | 1 | Daniela A. BotaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03681028 | Feasibility of Individualized Therapy for Recurrent Glioblastoma | completed | Phase 1 | 30 | Jennifer ClarkeOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04822688 | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | completed | — | 141 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03048240 | INtraoperative photoDYnamic Therapy of GliOblastoma(INDYGO) | completed | N/A | 10 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02617745 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid(GLIOPLAK) | completed | Phase 2 | 244 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05735171 | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence(SupraGlio-AI) | completed | N/A | 20 | Hospital del Rio HortegaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04566185 | Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma(EVA DOPA) | completed | N/A | 14 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06451042 | FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)(FET-TREAT) | completed | — | 11 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05432375 | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | completed | Early Phase 1 | 10 | Mundipharma Research LimitedINDUSTRY | 2 | Dec 10, 2025 | clinicaltrials |
| NCT04391062 | Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma(DOSINDYGO) | completed | Phase 2 | 14 | University Hospital, LilleOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
| NCT01582269 | A Study in Recurrent Glioblastoma (GB) | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT03532295 | Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03746080 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | completed | Phase 2 | 21 | Lawrence D RechtOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04826393 | ASP8374 + Cemiplimab in Recurrent Glioma | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03426891 | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT04074746 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | completed | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05608395 | 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)(GlioMET) | completed | Phase 2 | 33 | Masaryk Memorial Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03050736 | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | completed | Phase 2 | 29 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05190315 | Chlorpromazine and Standard of Care in Glioblastoma | completed | Phase 1 | 10 | Mohammed MilhemOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 55 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02717962 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | completed | Phase 2 | 118 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03679754 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | completed | Phase 1 | 36 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 30, 2026source: clinicaltrials